 NASHVILLE, Tenn., Dec. 03, 2020 GLOBE NEWSWIRE -- Harrow Health, Inc. NASDAQ: HROW today announced that a study featuring its patented MKO Melt formulation has been published in the American Association of Nurse Anesthetists AANA Journal. Each sublingually administered MKO Melt troche contains 3 mg of midazolam, 25 mg of ketamine, and 2 mg of ondansetron, and is available for institutional purchase through Harrows wholly-owned subsidiary, ImprimisRx. 